A Phase 2 interventional study of relatlimab+nivolumab and relatlimab+nivolumab+rHuPH20 in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 31 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing relatlimab in Melanoma — 6 open to participants now, 10 under way, 1 of them phase 3. relatlimab · Melanoma.
Among the 16 studies testing relatlimab in Melanoma, this one is the 4th largest by enrollment, is one of 5 that started in 2023, is one of 10 in phase 2, and was the 11th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →6 of the 16 studies testing relatlimab in Melanoma are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
relatlimab: first FDA approval 2022 (OPDUALAG), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 2 · Phase 4 1
First in 2015; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 48 across the 16 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 9 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 40th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2023, is one of 25 in phase 2, and was the 106th registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
1 of the studies testing relatlimab in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing relatlimab in Melanoma, from their registry updates:
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: relatlimab+nivolumab · Drug: relatlimab+nivolumab+rHuPH20
Drug: nivolumab · Drug: nivolumab+rHuPH20
Drug pages: Relatlimab · Nivolumab
Specified dose on specified days
Also known as: BMS-986213, Opdualag
Drug pages: Relatlimab · Nivolumab · Hyaluronidase (human recombinant)
Specified dose on specified days
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Drug pages: Nivolumab · Hyaluronidase (human recombinant)
Specified dose on specified days
Also known as: BMS-986298
Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose
PEPQ included 7 items 1. Pain or Discomfort (rated on 1 to 10 scale), 2. Length of time related to administration 3. Length of time related to administration impact amount of time to speak to doctor or nurse about illness or concern 4. Length of time for administration impact time to interact or socialize with other individuals 5. Convenience 6. Satisfaction 7. Choice of which route of administration would be preferred. 95% CI exact confidence interval was reported.
Time frame: Cycle 4 Day 1 (each cycle consist of 4 weeks)
Number of Participants With Adverse Events and Deaths
An adverse event is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.
Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 16 months)
Number of Participants With Laboratory Abnormalities and Immune Mediate Adverse Event
Time frame: From first dose (Day 1) and up to study completion (up to approximately 45 months)
| Milestone | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma |
|---|---|---|
| Started | 50 | 50 |
| Completed | 0 | 4 |
| Not completed | 50 | 46 |
| Withdrew: Ongoing treatment | 23 | 37 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Progressive disease | 18 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 7 | 4 |
| Withdrew: Other reasons | 0 | 1 |
PEPQ included 7 items 1. Pain or Discomfort (rated on 1 to 10 scale), 2. Length of time related to administration 3. Length of time related to administration impact amount of time to speak to doctor or nurse about illness or concern 4. Length of time for administration impact time to interact or socialize with other individuals 5. Convenience 6. Satisfaction 7. Choice of which route of administration would be preferred. 95% CI exact confidence interval was reported.
| percentage of partcipants | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma |
|---|---|---|
| Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose | 78.0 (62.4 to 89.4) | 70.8 (55.9 to 83.0) |
An adverse event is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.
| Participants | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma |
|---|---|---|
| Adverse Events | 47 | 47 |
| Serious Adverse Events | 16 | 5 |
| Drug related Adverse Events | 40 | 36 |
| Adverse events leading to discontinuation | 3 | 5 |
| Injection or infusion related adverse events | 14 | 14 |
| Deaths | 0 | 0 |
| Other Events of Special Interest - Myasthenic syndrome | 1 | 0 |
Results for this outcome have not been posted.
Collected over AE, SAEs and all cause mortality was collected from first dose (Day 1) until primary completion date (up to approximately 17 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Metastatic Melanoma | 8/50 (16%) | 21/50 (42%) | 44/50 (88%) |
| Cohort 2: Resected Melanoma | 2/50 (4%) | 6/50 (12%) | 41/50 (82%) |
| Event | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma |
|---|---|---|
| Adrenal insufficiencyEndocrine disorders | 2/50 | 0/50 |
| Acute kidney injuryRenal and urinary disorders | 2/50 | 0/50 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/50 | 0/50 |
| Cardiac arrestCardiac disorders | 1/50 | 0/50 |
| Immune-mediated hyperthyroidismEndocrine disorders | 0/50 | 1/50 |
| Abdominal painGastrointestinal disorders | 1/50 | 0/50 |
| AscitesGastrointestinal disorders | 1/50 | 0/50 |
| ConstipationGastrointestinal disorders | 0/50 | 1/50 |
| DiarrhoeaGastrointestinal disorders | 1/50 | 0/50 |
| Intestinal obstructionGastrointestinal disorders | 1/50 | 0/50 |
| Event | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/50 | 16/50 |
| FatigueGeneral disorders | 14/50 | 7/50 |
| DiarrhoeaGastrointestinal disorders | 10/50 | 13/50 |
| AstheniaGeneral disorders | 12/50 | 10/50 |
| HypothyroidismEndocrine disorders | 10/50 | 6/50 |
| NauseaGastrointestinal disorders | 10/50 | 4/50 |
| PruritusSkin and subcutaneous tissue disorders | 8/50 | 10/50 |
| Decreased appetiteMetabolism and nutrition disorders | 8/50 | 2/50 |
| PyrexiaGeneral disorders | 6/50 | 2/50 |
| Abdominal painGastrointestinal disorders | 4/50 | 5/50 |
| Age, Customized(Participants) | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma | Total |
|---|---|---|---|
| < 65 | 26 | 22 | 48 |
| >= 65 | 24 | 28 | 52 |
| Sex: Female, Male(Participants) | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma | Total |
|---|---|---|---|
| Female | 19 | 28 | 47 |
| Male | 31 | 22 | 53 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 3 | 11 | 14 |
| NOT HISPANIC OR LATINO | 40 | 39 | 79 |
| NOT REPORTED | 7 | 0 | 7 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Metastatic Melanoma | Cohort 2: Resected Melanoma | Total |
|---|---|---|---|
| White | 42 | 50 | 92 |
| Asian | 1 | 0 | 1 |
| Not reported | 7 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Nov 2023 to primary completion in Apr 2025, 17 months.
Results were first posted in Apr 2026, 11 months after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 17 months is below that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Nivolumab · Hyaluronidase (human recombinant)